MX2011007986A - Formulaciones orales solidas de una pirido-pirimidinona. - Google Patents

Formulaciones orales solidas de una pirido-pirimidinona.

Info

Publication number
MX2011007986A
MX2011007986A MX2011007986A MX2011007986A MX2011007986A MX 2011007986 A MX2011007986 A MX 2011007986A MX 2011007986 A MX2011007986 A MX 2011007986A MX 2011007986 A MX2011007986 A MX 2011007986A MX 2011007986 A MX2011007986 A MX 2011007986A
Authority
MX
Mexico
Prior art keywords
solid oral
pyridopyrimidinone
oral formulations
thyl
pyrido
Prior art date
Application number
MX2011007986A
Other languages
English (en)
Inventor
Rajinder Singh
Daya Verma
Yue Helen Teng
Dan Thompson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42125930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011007986(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2011007986A publication Critical patent/MX2011007986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Pyridine Compounds (AREA)
  • Centrifugal Separators (AREA)

Abstract

Una formulación farmacéutica de dosificación oral sólida de la (R)-2-amino-7-[4-fluoro-2-(6-metoxi-piridin-2-il)-fenil]-4-metil- 7,8-dihidro-6H-pirido-[4,3-d]-pirimidin-5-ona o su sal; y un tensoactivo o un ácido.
MX2011007986A 2009-01-29 2010-01-28 Formulaciones orales solidas de una pirido-pirimidinona. MX2011007986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14816009P 2009-01-29 2009-01-29
PCT/US2010/022335 WO2010088336A1 (en) 2009-01-29 2010-01-28 Solid oral formulations of a pyridopyrimidinone

Publications (1)

Publication Number Publication Date
MX2011007986A true MX2011007986A (es) 2011-08-15

Family

ID=42125930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007986A MX2011007986A (es) 2009-01-29 2010-01-28 Formulaciones orales solidas de una pirido-pirimidinona.

Country Status (22)

Country Link
US (2) US20110287069A1 (es)
EP (1) EP2391346A1 (es)
JP (1) JP2012516346A (es)
KR (1) KR20110115592A (es)
CN (1) CN102300559A (es)
AR (1) AR075180A1 (es)
AU (1) AU2010208270B2 (es)
BR (1) BRPI1007515A2 (es)
CA (1) CA2749533A1 (es)
CO (1) CO6410282A2 (es)
EC (1) ECSP11011286A (es)
IL (1) IL213872A0 (es)
MA (1) MA33061B1 (es)
MX (1) MX2011007986A (es)
NZ (1) NZ594035A (es)
PE (1) PE20120422A1 (es)
RU (1) RU2011135424A (es)
SG (2) SG10201500697WA (es)
TN (1) TN2011000351A1 (es)
TW (1) TW201031411A (es)
WO (1) WO2010088336A1 (es)
ZA (1) ZA201104894B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
US20200155455A1 (en) * 2017-04-13 2020-05-21 Pharmako Biotechnologies Pty Limited Cold-water-dispersible chemical delivery system
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
CA2474838C (en) * 2002-02-01 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060068007A1 (en) * 2004-09-24 2006-03-30 Boehringer Ingelheim Pharmaceuticals, Inc. Class of surfactant-like materials
EP1845953A1 (en) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
JO2783B1 (en) 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
US20070104778A1 (en) * 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
WO2007068615A2 (en) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
EP2146577A1 (en) * 2007-05-18 2010-01-27 Scidose, Llc Ziprasidone formulations
AU2008313727A1 (en) * 2007-10-18 2009-04-23 Novartis Ag CSF-1R inhibitors for treatment of cancer and bone diseases

Also Published As

Publication number Publication date
JP2012516346A (ja) 2012-07-19
ECSP11011286A (es) 2011-09-30
TN2011000351A1 (en) 2013-03-27
CN102300559A (zh) 2011-12-28
CO6410282A2 (es) 2012-03-30
AU2010208270B2 (en) 2014-01-16
NZ594035A (en) 2013-09-27
SG10201500697WA (en) 2015-04-29
MA33061B1 (fr) 2012-02-01
ZA201104894B (en) 2012-03-28
SG172813A1 (en) 2011-08-29
US20110287069A1 (en) 2011-11-24
AR075180A1 (es) 2011-03-16
KR20110115592A (ko) 2011-10-21
CA2749533A1 (en) 2010-08-05
EP2391346A1 (en) 2011-12-07
RU2011135424A (ru) 2013-03-10
PE20120422A1 (es) 2012-05-03
AU2010208270A1 (en) 2011-07-21
TW201031411A (en) 2010-09-01
US20140044788A1 (en) 2014-02-13
IL213872A0 (en) 2011-07-31
WO2010088336A1 (en) 2010-08-05
BRPI1007515A2 (pt) 2016-02-23

Similar Documents

Publication Publication Date Title
TN2011000351A1 (en) Solid oral formulations of a pyridopyrimidinone
WO2011012816A3 (fr) Formulation pharmaceutique
EP3626253A3 (en) Stable formulations of linaclotide
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
IL220679A (en) Method of manufacture of solid preparations containing basic active pharmaceutical ingredients and the solid preparations produced by the method
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
PL2046944T3 (pl) Mieszanina bakterii kwasu mlekowego do wytwarzania bezglutenowych produktów piekarniczych
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
MY159492A (en) Solid pharmaceutical formulation with delayed release
AU2012280198A8 (en) Darunavir combination formulations
MX341976B (es) Formulaciones de darunavir.
IL205313A0 (en) Pharmaceutical formulation of clavulanic acid
ZA201107412B (en) Methods for the preparation of [2-8,9-dioxo2,6-diazabicyclo[5.2.0]non-1(1)-en-2-yl)ethyl]phosphonic acid and precursors thereof
WO2009060952A1 (ja) 新規製剤
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
TN2012000105A1 (en) Spirolactam derivatives and uses of same
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2010077669A3 (en) Palonosetron formulation
HK1122731A1 (en) Prolonged release formulation of active pharmaceutical ingredients

Legal Events

Date Code Title Description
FA Abandonment or withdrawal